Key Points
- Meredith Cook, VP of ANI Pharmaceuticals, sold 500 shares on April 13 at an average price of $77.95 for $38,975, reducing her stake by 0.63% to 78,890 shares valued at about $6.15M; the sale was executed under a pre-arranged Rule 10b5-1 plan.
- The April sale follows two other 500-share disposals by Cook on Jan. 13 ($84.33) and Mar. 13 ($72.62), suggesting a pattern of scheduled insider sales.
- ANIP has a market cap of $1.75B, a one-year trading range of $56.71–$99.50, and a consensus analyst rating of Moderate Buy with an average target of $107.33 (Guggenheim recently raised its target to $124).
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $77.95, for a total value of $38,975.00. Following the sale, the vice president directly owned 78,890 shares in the company, valued at $6,149,475.50. The trade was a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Friday, March 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $72.62, for a total value of $36,310.00.
- On Tuesday, January 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $84.33, for a total value of $42,165.00.
ANI Pharmaceuticals Price Performance
Shares of ANIP opened at $78.31 on Tuesday. ANI Pharmaceuticals, Inc. has a 1 year low of $56.71 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of 23.31 and a beta of 0.44. The business has a 50-day moving average of $76.35 and a 200-day moving average of $82.25.
Analysts Set New Price Targets
ANIP has been the subject of a number of analyst reports. Guggenheim raised their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Weiss Ratings restated a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 14th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 6th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $107.33.
View Our Latest Stock Analysis on ANI Pharmaceuticals
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. increased its holdings in ANI Pharmaceuticals by 1,821.1% in the fourth quarter. Pacer Advisors Inc. now owns 79,919 shares of the specialty pharmaceutical company's stock worth $6,309,000 after purchasing an additional 75,759 shares in the last quarter. Invesco Ltd. increased its holdings in ANI Pharmaceuticals by 26.0% in the fourth quarter. Invesco Ltd. now owns 189,836 shares of the specialty pharmaceutical company's stock worth $14,986,000 after purchasing an additional 39,178 shares in the last quarter. XTX Topco Ltd bought a new stake in ANI Pharmaceuticals in the fourth quarter worth approximately $1,243,000. Susquehanna Portfolio Strategies LLC bought a new stake in ANI Pharmaceuticals in the fourth quarter worth approximately $906,000. Finally, Tang Capital Management LLC increased its holdings in ANI Pharmaceuticals by 51.6% in the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company's stock worth $38,005,000 after purchasing an additional 163,937 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
